# US 2001/0024649 A1 · Method to enhance the immunogenicity of an antigen

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0024649 A1
- Document ID: US20010024649A1
- Status: Published application
- Kind: A1
- Application number: 09/809,158
- Filed: 2001-03-15
- Published: 2001-09-27
- Earliest claimed: 1998-10-20
- Assignees: Torrey Pines Institute for Molecular Studies
- Inventors: Carol O. Cowing
- Web page: https://patentgrep.com/patent/US20010024649A1

## CPC

- A61K 9/0009: {involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis}
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 39/0011: {Cancer antigens}
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 41/0047: {Sonopheresis, i.e. ultrasonically-enhanced transdermal delivery, electroporation of a pharmacologically active agent}
- A61P 37/04: Immunostimulants
- A61K 47/08: containing oxygen, {e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides}
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61K 47/18: Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K 47/186: {Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide}
- A61K 47/20: containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/54: {characterised by the route of administration}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention is related to a method for enhancing the immunogenicity of an antigen in a mammal by introducing into the mammal an antigen or a portion thereof and administering to the mammal a treatment that increases antigen presentation in a lymphoid organ.

## Claims

### Claim 1

A method for vaccinating a mammal against an antigen, comprising:
introducing into the mammal an effective dose of the antigen or an epitope(s) thereof; and
administering to the mammal a topical treatment in an amount sufficient to increase the number of antigen-bearing dendritic cells in a lymphoid organ,
wherein introducing the antigen and administering the treatment are performed independently in any order.

### Claim 2 (depends on 1)

The method of claim 1, wherein the topical treatment comprises a lipophilic molecule capable of traversing the stratum corneum and inducing immature dendritic cells to migrate to the draining lymphoid organ.

### Claim 3 (depends on 2)

The method of claim 2, wherein the lipophilic molecule is selected from the following formulas: 3
wherein R1 and R2 are independently alkyl side chains containing 1 to 16 carbon atoms, C1 to C16 substituted alkyl, C3 to C10 cycloalkyl, C3 to C10 substituted cycloalkyl, C2 to C10 alkenyl, C2 to C10 substituted alkenyl, C2 to C10 alkynyl, C2 to C10 substituted alkynyl;
wherein R3, R3′, R4 and R4′ are selected independently from the group consisting of hydrogen atom, hydroxy group, halogeno group, alkyl side chains containing 1 to 16 carbon atoms, C1 to C16 substituted alkyl, C3 to C10 cycloalkyl, C3 to C10 substituted cycloalkyl, C2 to C10 alkenyl, C2 to C10 substituted alkenyl, C2 to C10 alkynyl, C2 to C10 substituted alkynyl, C7 to C16 phenylalkyl, C7 to C16 substituted phenylalkyl, phenyl, substituted phenyl, naphthyl and substituted naphthyl;
wherein X is an oxygen or a nitrogen atom; and
wherein W is a saturated or unsaturated chain consisting of C1-C10 alkyl, C1-C10 substituted alkyl, C7-C10 phenylalkyl, C7-C16 substituted phenylalkyl, phenyl, substituted phenyl, naphthyl, substituted naphthyl, C3-C7 cycloalkyl and C3-C7 substituted cycloalkyl group, and wherein each terminus of the chain is bonded to the carbon C(R3R3′) and C(R4R4′).

### Claim 4 (depends on 3)

The method of claim 3, wherein W contains one or more heteroatoms selected from the group consisting of nitrogen, sulfur, and oxygen in combination or independently.

### Claim 5 (depends on 3)

The method of claim 3, wherein the R1 and R2 groups are identical C1 to C6 alkyl moieties.

### Claim 6 (depends on 3)

The method of claim 3, wherein R1 and R2 are (CH2)3—CH3.

### Claim 7 (depends on 3)

The method of claim 3, wherein X is an oxygen and R3 and R4 are linked to form a ring structure which, including the W chain, comprises a saturated or unsaturated C3 to C10 cycloalkyl, C3 to C10 substituted cycloalkyl, C7 to C16 phenylalkyl, C7 to C16 substituted phenylalkyl, phenyl, substituted phenyl, naphthyl or substituted naphthyl.

### Claim 8 (depends on 7)

The method of claim 7, wherein the ring structure is an aryl group.

### Claim 9 (depends on 7)

The method of claim 7, wherein the ring structure contains one or more heteroatoms selected from the group consisting of nitrogen, sulfur, and oxygen.

### Claim 10 (depends on 3)

The method of claim 3, wherein the lipophilic molecule comprises a terpene.

### Claim 11 (depends on 2)

The method of claim 2, wherein the lipophilic molecule is selected from the group consisting of dibutyl phthalate, dibutyl-D-tartarate, N,N-diethyl-toluamide, dibutylfumarate, di(2-ethylhexyl)fumarate, diisooctylmaleate, diethylhexylmaleate, diisooctylfumarate, benzoic acid, bihenylmaleate, dioctylphthalate, dibutylmaleate, dioctymaleate, dibutylsuccinate, dioctylsuccinate, dinonylphthalate, diisononylphthalate, dimethylphthalate, diethylphthalate, dipropylphthalate, diphenylphthalate, dibenzylbutylphthalate, diethylmethylphthalate and camphor.

### Claim 12 (depends on 2)

The method of claim 2, wherein the lipophilic molecule is <500 daltons.

### Claim 13 (depends on 2)

The method of claim 2, wherein the lipophilic molecule has an oil/water partition coefficient >1.

### Claim 14 (depends on 13)

The method of claim 13, wherein the lipophilic molecule has an oil/water partition coefficient of between about 10 and about 106.

### Claim 15 (depends on 2)

The method of claim 2, wherein the topical treatment further comprises an organic solvent.

### Claim 16 (depends on 15)

The method of claim 15, wherein the organic solvent is acetone.

### Claim 17 (depends on 1)

The method of claim 1, wherein the topical treatment comprises application of ultrasound energy.

### Claim 18 (depends on 1)

The method of claim 1, wherein the antigen or epitope(s) thereof is introduced into the mammal by a virus, a bacterium, a fungus, or a parasite.

### Claim 19 (depends on 1)

The method of claim 1, wherein the antigen or epitope(s) thereof is introduced into the mammal by ingestion.

### Claim 20 (depends on 1)

The method of claim 1, wherein the antigen or epitope(s) thereof is introduced into the mammal by disrupting the stratum corneum.

### Claim 21 (depends on 1)

The method of claim 1, wherein the antigen or epitope(s) thereof is introduced into the mammal by injection.

### Claim 22 (depends on 21)

The method of claim 21, wherein the injection is made via a route selected from the group consisting of intraepidermal, intradermal, subcutaneous, intramuscular, intravascular, or into a specific organ.

### Claim 23 (depends on 1)

The method of claim 1, wherein the antigen or epitope(s) thereof is introduced into the mammal via delivery to at least a portion of the respiratory, urogenital or gastrointestinal tracts.

### Claim 24 (depends on 1)

The method of claim 1, wherein the antigen or epitope(s) thereof is introduced into the mammal by a transfer of cells containing the antigen or epitope(s) thereof.

### Claim 25 (depends on 1)

The method of claim 1, wherein the antigen or epitope(s) thereof is introduced into the mammal by transformation of a cell within the mammal and expression of the antigen or epitope(s) thereof by the transformed cell.

### Claim 26 (depends on 25)

The method of claim 25, wherein the transformation is induced by the transfer of a nucleic acid encoding the antigen or epitope(s) thereof.

### Claim 27 (depends on 1)

The method of claim 1, wherein the antigen or epitope(s) thereof is endogenous to the mammal and is either normal or pathologic.

### Claim 28 (depends on 1)

The method of claim 1, wherein the amount of topical treatment is sufficient to increase in the number of antigen-bearing dendritic cells in the lymphoid organ by a factor of about 2 to about 1000 times the number of resident dendritic cells in an untreated mammal.

### Claim 29 (depends on 28)

The method of claim 28, wherein the number of antigen-bearing dendritic cells in the lymphoid organ is increased by a factor of about 5 to about 100 times the number of resident dendritic cells in an untreated mammal.

### Claim 30 (depends on 1)

The method of claim 1, wherein the amount of topical treatment is further characterized as being sufficient to increase local release of an endogenous inducer of dendritic cell migration and maturation.

### Claim 31 (depends on 1)

The method of claim 1, wherein the amount of topical treatment is further characterized as being sufficient to alter the plasma membrane expression or function of an adhesion molecule.

### Claim 32

A method of immunization against an antigen in a mammal, comprising:
introducing into the mammal an expression vector adapted to induce the prolonged expression of the antigen or epitope thereof; and
administering a topical treatment to the mammal during a period when the antigen is being expressed, wherein the topical treatment is administered in an amount sufficient to increase the number of antigen-bearing dendritic cells in a draining lymphoid organ.

### Claim 33 (depends on 32)

The method of claim 32 wherein the antigen or epitope(s) thereof is endogenous to the mammal.

### Claim 34 (depends on 32)

The method of claim 32 wherein the topical treatment is administered repeatedly at periodic intervals during the period when the antigen is being expressed.

### Claim 35 (depends on 32)

The method of claim 32, wherein the topical treatment comprises a lipophilic molecule capable of traversing the stratum corneum and inducing immature dendritic cells to migrate to the draining lymphoid organ.

### Claim 36 (depends on 35)

The method of claim 35, wherein the lipophilic molecule is selected from the following formulas: 4
wherein R1 and R2 are independently alkyl side chains containing 1 to 16 carbon atoms, C1 to C16 substituted alkyl, C3 to C10 cycloalkyl, C3 to C10 substituted cycloalkyl, C2 to C10 alkenyl, C2 to C10 substituted alkenyl, C2 to C10 alkynyl, C2 to C10 substituted alkynyl;
wherein R3, R3′, R4 and R4′ are selected independently from the group consisting of hydrogen atom, hydroxy group, halogeno group, alkyl side chains containing 1 to 16 carbon atoms, C1 to C16 substituted alkyl, C3 to C10 cycloalkyl, C3 to C10 substituted cycloalkyl, C2 to C10 alkenyl, C2 to C10 substituted alkenyl, C2 to C10 alkynyl, C2 to C10 substituted alkynyl, C7 to C16 phenylalkyl, C7 to C16 substituted phenylalkyl, phenyl, substituted phenyl, naphthyl and substituted naphthyl;
wherein X is an oxygen or a nitrogen atom; and
wherein W is a saturated or unsaturated chain consisting of C1-C10 alkyl, C1-C10 substituted alkyl, C1-C10 phenylalkyl, C7-C16 substituted phenylalkyl, phenyl, substituted phenyl, naphthyl, substituted naphthyl, C3-C7 cycloalkyl and C3-C7 substituted cycloalkyl group, and wherein each terminus of the chain is bonded to the carbon C(R3R3′) and C(R4R4′).

### Claim 37 (depends on 36)

The method of claim 36, wherein W contains one or more heteroatoms selected from the group consisting of nitrogen, sulfur, and oxygen in combination or independently.

### Claim 38 (depends on 36)

The method of claim 36, wherein the R1 and R2 groups are identical C1 to C6 alkyl moieties.

### Claim 39 (depends on 36)

The method of claim 36, wherein R1 and R2 are (CH2)3—CH3.

### Claim 40 (depends on 36)

The method of claim 36, wherein X is an oxygen and R3 and R4 are linked to form a ring structure which, including the W chain, comprises a saturated or unsaturated C3 to C10 cycloalkyl, C3 to C10 substituted cycloalkyl, C7 to C16 phenylalkyl, C7 to C16 substituted phenylalkyl, phenyl, substituted phenyl, naphthyl or substituted naphthyl.

### Claim 41 (depends on 36)

The method of claim 36, wherein the ring structure is an aryl group.

### Claim 42 (depends on 36)

The method of claim 36, wherein the ring structure contains one or more heteroatoms selected from the group consisting of nitrogen, sulfur, and oxygen.

### Claim 43 (depends on 35)

The method of claim 35, wherein the lipophilic molecule comprises a terpene.

### Claim 44 (depends on 35)

The method of claim 35, wherein the lipophilic molecule is selected from the group consisting of dibutyl phthalate, dibutyl-D-tartarate, N,N-diethyl-toluamide, dibutylfumarate, di(2-ethylhexyl)fumarate, diisooctylmaleate, diethylhexylmaleate, diisooctylfumarate, benzoic acid, bihenylmaleate, dioctylphthalate, dibutylmaleate, dioctymaleate, dibutylsuccinate, dioctylsuccinate, dinonylphthalate, diisononylphthalate, dimethylphthalate, diethylphthalate, dipropylphthalate, diphenylphthalate, dibenzylbutylphthalate, diethylmethylphthalate and camphor.

### Claim 45 (depends on 35)

The method of claim 35, wherein the lipophilic molecule is <500 daltons.

### Claim 46 (depends on 35)

The method of claim 35, wherein the lipophilic molecule has an oil/water partition coefficient >1.

### Claim 47 (depends on 46)

The method of claim 46, wherein the lipophilic molecule has an oil/water partition coefficient of between about 10 and about 106.

### Claim 48 (depends on 35)

The method of claim 35, wherein the topical treatment further comprises an organic solvent.

### Claim 49 (depends on 48)

The method of claim 48, wherein the organic solvent is acetone.

### Claim 50 (depends on 32)

The method of claim 32, wherein the topical treatment comprises application of ultrasound energy.

### Claim 51

A method for vaccinating a mammal against an antigen, comprising:
injecting into the mammal an effective dose of the antigen or an epitope(s) thereof; and
administering to the mammal a topical treatment in an amount sufficient to increase the number of antigen-bearing dendritic cells in a draining lymphoid organ,
wherein the topical treatment comprises a lipophilic molecule with a molecular weight of <500 daltons.

### Claim 52

A method for enhancing an immune response in a mammal against an endogenous antigen, comprising repeated topical application to the mammal of a lipophilic compound having a molecular weight <500 daltons, wherein the lipophilic compound is applied in an amount sufficient to increase the number of antigen-bearing dendritic cells in a lymphoid organ.

### Claim 53 (depends on 52)

The method of claim 52, wherein said endogenous antigen is a tumor antigen.

### Claim 54

A method for vaccinating a mammal against an antigen, comprising:
delivering to the mammal a nucleic acid vaccine, comprising DNA or RNA encoding the antigen or an epitope(s) thereof; and
administering to the mammal a topical treatment in an amount sufficient to increase the number of antigen-bearing dendritic cells in a lymphoid organ,
wherein the topical treatment comprises a lipophilic molecule with a molecular weight of <500 daltons.

### Claim 55

A method for vaccinating a mammal against an antigen, comprising:
providing the mammal with an effective dose of the antigen or an epitope(s) thereof; and
administering internally to the mammal a treatment in an amount sufficient to increase the number of antigen-bearing dendritic cells in a lymphoid organ.

### Claim 56 (depends on 55)

The method of claim 55, wherein administering the treatment internally occurs via a route selected from the group consisting of injection, delivery into an organ, and delivery to the gastrointestinal, respiratory or urogenital tracts.

### Claim 57 (depends on 55)

The method of claim 55, wherein the treatment comprises a lipophilic molecule with a molecular weight of <500 daltons or low frequency ultrasound energy.
